



Serological Tests for FMDV a WRL perspective

Anna Ludi

Anna.Ludi@pirbright.ac.uk

Importance of understanding:



- (1) the intended use
 - (2) the limitations
- &

Main Purpose of Serological Tests

Four main purposes defined in the OIE Terrestrial Manual



1. To certify individual animals prior to import or export (i.e. for trade)
2. To confirm suspected cases of FMD
3. To substantiate absence of infection
4. To demonstrate the efficacy of vaccination

** key point – “cut-offs may be set at different threshold for herd-based sero-surveillance than is appropriate for certifying freedom from infection for individual animals for the purpose of international trade.”

*OIE Terrestrial Manual 2018, Chapter 3.1.8



SEA: outbreaks of Serotype Asia 1

- Serotype Asia 1 not reported in Southeast Asia since 2006/7(?)
- February 2017: FMD outbreaks in cattle in Myanmar
- Sequence data from RRL-SEA in Pakchong, Thailand
- New introduction of the virus from Pool 2
- Asia 1 component had been removed from the vaccine



SEA: outbreaks of Serotype Asia 1

? Is there evidence that the Asia 1 serotype has spread more widely in Myanmar



Looking for evidence of Asia 1 infection in Myanmar



- Two recent serosurveys:
 1. 2016/2017 – cattle (NZ Project)
 2. 2018 – multiple species (OIE Project)
- Samples screened for NSP (PrioCheck) and Asia 1 specific antibodies (LPBE)



Looking for evidence of Asia 1 infection in Myanmar

- Representative LPBE positive sera (**n = 204**) sent to WRLFMD for confirmation by **VNT** (Asia 1 Shamir virus)

RESULTS

- Very few Asia 1 antibody-positives
- *NZ data: 6 positives, 5 inconclusive, 40 negative*
- *OIE Data: 1 positive, 8 inconclusive, 143 negative (1 test failure)*

Serological Assays

- Non-structural protein ELISA (NSP)  Non-Structural Protein ELISA
 - Liquid Phase Blocking ELISA (LPBE)
 - Solid Phase Competition ELISA (SPCE)
 - Virus Neutralisation Test (VNT)
 - Vaccine Matching VNT
- 
- Structural Protein ELISA

Others (not covered):

- Complement Fixation Test
- Agar gel immunodiffusion
- Avidity ELISA
- Isotype ELISA

Purpose according to OIE Terrestrial Manual



| | NSP Ab | SP Ab | VNT |
|---|-----------|----------|-----|
| Population Freedom From Infection | +++ | ++ | ++ |
| Individual Animal Freedom From Infection Prior To Movement | ++ | ++ | ++ |
| Contribute To Eradication Policies | +++ | +++ | +++ |
| Confirmation of Clinical Cases | +++ | +++ | +++ |
| Prevalence Of Infection – Surveillance | +++ | ++ | ++ |
| Immune Status In Individual Animals Or Populations Post-Vaccination | - | +++ | +++ |

KEY:

+++ recommended, validated for the purposes shown


++ suitable method but may need further validation

- Not appropriate for this purpose



Measures:
Total **Structural**
Antibodies

Structural Protein ELISA



Liquid Phase Blocking ELISA

How does it work?

A new enzyme-linked immunosorbent assay (ELISA)
for the detection of antibodies against
foot-and-mouth disease virus
I. Development and method of ELISA
C. Hamblin *, I.T.R. Barnett and R.S. Hedger
Department of Virus Diagnosis, Pirbright Institute, Pirbright, Woking, Surrey GU24 0NF, U.K.
(Received 13 March 1986, accepted 12 May 1986)




Fig. 1. Flow diagram of the liquid-phase blocking sandwich ELISA.


Solid Phase Competition ELISA

How does it work?




Ready-to-use

FMD virus trapped by anti-FMDV type-specific MAb



1 h


Incubation of sample and control sera



without washing

1 h

Addition of anti-FMDV type-specific MAb peroxidase-conjugated




washin



g

20 min.


Incubation of chromogen substrate and color development



**POSITIVE
SERUM**




without washing



washin

g



**NEGATIV
E
SERUM**

LPBE vs SPCE




| | LPBE | SPCE |
|--------------------------------|-----------------------------|---------------------------|
| MAIN USES | | |
| Import/Export Testing | + | + |
| Vaccine Matching | + | - |
| Post-Outbreak Surveillance | + | + |
| Post Vaccination Monitoring*** | + | + |
| Availability | Individual reagents from RL | Commercial kits available |
| Optimization | yes | no |
| Validation | yes | yes |

*** No data is available on how ELISA data correlates directly to protection (more on this later)




Measures:
Neutralising Antibodies

Virus Neutralisation Test





Virus Neutralization Test - How does it work?



VNT – Advantages / Disadvantages





| Advantages | Disadvantages |
|------------------------------------|---|
| Strain specific | Live virus |
| Homologous and Heterologous titres | Cell culture essential |
| Little to no cross-reactivity | More variable and poorer repeatability than ELISA |

| MAIN USES | |
|--------------------------------|---|
| Import/Export Testing | + |
| Vaccine Matching | + |
| Post-Outbreak Surveillance | + |
| Post Vaccination Monitoring*** | + |

*** Data is available on how VNT titres correlate to protection (more on this later)


SEA: outbreaks of Serotype Asia 1

? Is there evidence that the Asia 1 serotype has spread more widely in Myanmar



Understanding discrepancy between LPBE & VNT


- Structural protein antibodies measured by LPBE and VNT target different epitopes
- VNT only detects neutralising antibodies (surface exposed at defined sites)
- LPBE detects a wider-range of epitopes and cannot distinguish between external and internal epitopes



How does this affect the diagnostic test results??

Understanding discrepancy between LPBE & VNT

- FMDV capsids are easily degraded
- Host polyclonal responses are directed at antigenic sites (contribute to neutralising responses), other surface “binding” epitopes and **epitopes exposed after capsid degradation**
- Serotypic determinants are on the outside of the capsid, while many internal epitopes are shared between serotypes



Is this why we see Serotypic Cross-reactivity?



‘The ability of an antibody to react with similar antigenic sites on different proteins’



O



A



Asia 1



C



SAT 1



SAT 2



SAT 3

ELISA set-up




| | | | | |
|--------------------|-------------|------------|------------|---|
| Liquid phase ELISA | TPI LPBE | In-house | Polyclonal | O, A, C, Asia 1, SAT 1, SAT 2 and SAT 3 |
| | TPI SPCE | | | O, A, C, Asia 1, SAT 1, SAT 2 and SAT 3 |
| Competition ELISA | IZSLER SPCE | Commercial | Monoclonal | O, A, Asia 1, SAT 1 and SAT 2 |
| | IDVet | | | O, A and Asia 1 |
| | PrioCHECK | | | O, A and Asia 1 |

9125 individual tests carried out!

Results (infected cattle)



Status of Animal (serotype O)




Status of Animal \Rightarrow

O


A

As 1


IZSLER




LPBE




SPCE



IDVet



PrioCHECK



Assay Serotype \Rightarrow

O, A, Asia 1

Highlights importance of serological validation



Specificity

- Test a negative cohort of sera – no vaccination, no infection
- Preferably from a region free from FMDV without vaccination

Sensitivity

- Experimentally infected/vaccinated animals of known serotype
- Monovalent infection/vaccination

Experimental Design

- Compare to another assay
- Run assays side by side under same conditions
- Insure staff are trained and competent to carry out validation
- Set acceptance criteria **before** testing takes place

Acknowledgements

- Support for the WRLFMD and research projects
- Collaborating FMD Reference Laboratories and field teams
- Partners within the OIE/FAO FMD Lab Network

Thank you

Photos courtesy of HDR Architecture, Inc.; © 2104 James Brittain

